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Abstract
We propose the replacement of endogenous epitopes with foreign epitopes to exploit the highly immunogenic hepatitis B surface antigen
(HBsAg) as a vaccine vector to elicit disease-protective cytotoxic T-lymphocyte (CTL) responses. Locations were defined within the HBsAg gene
where replacements of DNA encoding HBsAg epitopes may be made to generate functional recombinant (r) HBsAg DNA vaccines. We
demonstrate that rHBsAg DNA vaccines encoding multiple copies of a model tumor epitope from human papillomavirus (HPV) elicit enhanced
CTL responses compared to rHBsAg DNA vaccines encoding a single copy. We show that rHBsAg DNA vaccines elicit a marked prophylactic
and long-lived therapeutic protection against epitope expressing tumor, although protective efficacy was not improved by increasing the number of
copies of the tumor epitope DNA. These results demonstrate the efficacy of HBsAg as a vector for the delivery of foreign CTL epitopes using the
epitope replacement strategy, and have implications for rHBsAg vaccine design. The results also have implications for the derivation of a
therapeutic vaccine for HPV-associated squamous carcinoma.
© 2007 Elsevier Inc. All rights reserved.Keywords: Recombinant DNA vaccine; Hepatitis B surface antigen; Cytotoxic T lymphocyte; Tumor protection; Human papillomavirusIntroduction
The hepatitis B virus (HBV) small envelope protein
assembles with host-derived lipids into empty 22 nm virus-like
particles (VLPs), consisting of 100–150 subunits of the ca. 226
amino acid hepatitis B surface antigen (HBsAg) molecule,
without the participation of nucleocapsids. HBsAg VLPs induce
potent antibody and cytotoxic T lymphocyte (CTL) responses
when used for vaccination due to their particulate nature and
repeated sub-unit structure (Schirmbeck et al., 1994; Schirm-
beck and Reimann, 1996). HBsAg may also be delivered as a⁎ Corresponding author. Fax: +61 7 3636 1401.
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doi:10.1016/j.virol.2007.06.041DNA vaccine, where CTL induction by intracellular translated
HBsAg protein occurs through the ‘classical’ endogenous
pathway as well as though the ‘alternative’ pathway via secreted
HBsAg particles (Schirmbeck et al., 1995; Loirat et al., 2000).
HBsAg vaccines administered as DNA or VLPs mimic the
immunogenicity of live-attenuated vaccines, although they do
not share most of their perceived disadvantages and ethical
issues (e.g. threat to immunocompromised recipients, reversion
to virulence).
While the intrinsic immunogenicity of HBsAg has been
exploited as a carrier for the induction of antibody to foreign
whole antigens or epitopes inserted at the C′ terminus
(Berkower et al., 2004; Bisht et al., 2002; Baez-Astua et al.,
2005), the N′ terminus (Vreden et al., 1991; Puaux et al., 2004;
Bruss and Ganem, 1991) or in the hydrophilic ‘a’-loop (Netter
et al., 2001), the capacity of HBsAg to deliver foreign CTL
epitopes is less well explored. Using a strategy of epitope
replacement, we have recently demonstrated the powerful
efficacy of HBsAg as a vector to deliver foreign CTL epitopes
364 O. Haigh et al. / Virology 368 (2007) 363–375for the induction of insert-directed effector and memory CTL
responses (Woo et al., 2006). We reasoned that this approach
would predispose to the maintenance of spatial requirements
for correct conformation of the HBsAg molecule, and also to
the maintenance of appropriate antigen processing. Thus by
deletion of an individual endogenous HBsAg CTL epitope and
insertion of an individual foreign CTL epitope at the site of
deletion, we recently demonstrated the induction of protective
CTL responses for an infectious disease and for a carcinoma
(Woo et al., 2006).
A crucial question for the delivery of foreign CTL epitopes by
HBsAg vector is the amount of foreign epitope which must be
delivered to ensure a maximal response. In the present study, we
define five locations at which deletions of DNA encoding
endogenous CTL epitopes may be made and replaced with DNA
encoding a foreign tumor-protective CTL epitope to generate a
panel of recombinant (r) HBsAg DNAvaccines. We investigate
the efficacy of induction of CTL responses and disease
protection by rHBsAg DNA vaccines encoding a single copy
versus multiple copies of the tumor-protective CTL epitope.
We used an epitope of human papillomavirus (HPV) 16 E7
protein as a model tumor antigen. HPVs are associated with a
number of squamous cell cancers, most notably cervical
carcinoma. The oncogenic HPV E7 protein is responsible for
transforming epithelial cells by mechanisms that require E7 to
persist for cells to remain transformed (Tommasino and
Crawford, 1995; von Knebel et al., 1994). Thus, E7 is a
tumor associated antigen (TAA) to which CTL-inducing
immunoprotective strategies may be directed. CD8+ cytotoxic
T lymphocytes (CTLs) are crucial components of protective
immune responses to E7-associated tumors (von Knebel et al.,
1994).
We demonstrate that the HBsAg gene contains (at least) five
sites at which DNA encoding endogenous HBsAg CTL
epitopes may be excised, and replaced with DNA encoding a
E7 CTL epitope to elicit powerful effector and memory CTL
responses when administered as recombinant DNA vaccines.
We show that the rHBsAg DNA vaccine elicits potent
prophylactic and long-lived therapeutic protection against E7-
expressing tumor. We show that when used at a standard doses,
rHBsAg DNA encoding multiple copies of the E7 epitope elicitFig. 1. Schematic of the 226 amino acid HBsAg-s molecule depicting the location of
internal domains (see Table 1 for details of epitopes).superior CTL responses measured in vitro compared to rHBsAg
DNA vaccine coding a single copy, though these enhanced
responses were not associated with improved tumor protection.
Our findings underscore the efficacy of HBsAg as a vector for
the delivery of foreign CTL epitopes, using the epitope
replacement strategy. They address the potency of rHBsAg
vaccines containing single versus multiple copies of a foreign
epitope, and so have generic implications for rHBsAg vaccine
design. The results also have specific implications for the
derivation of a therapeutic vaccine for HPV-associated squa-
mous carcinomas.
Results
Immunization with rHBsAg DNA encoding a foreign CTL
epitope inserted at any one of five locations elicits
insert-directed CTLs
A number of HBsAg CTL epitopes in transmembrane and
internal regions of the HBsAg molecule restricted through
murine (Schirmbeck et al., 1995, 2002) and human (Loirat et al.,
2000) MHC class 1 molecules have been described. In a first set
of experiments, we created 5 constructs in each of which one of
the more immunogenic of these HBsAg-specific CTL epitopes
(VLQ, IPQ, FLG, GLS and SIL; Fig. 1 and Table 1) was deleted
and replaced with the tumor-protective CTL epitope RAH
(49RAHYNIVTF57) from the E7 protein of HPV16 (Feltkamp et
al., 1993). Thus, five recombinant HBsAg DNA vaccines were
derived, each containing a single copy of the RAH minigene.
We asked whether these rHBsAg DNA vaccines would elicit
RAH-directed effector and memory CTL responses.
To investigate effector responses we quantified epitope-
specific interferon-gamma (IFN-γ) secretion of ex vivo spleno-
cytes by ELISPOT assay. Ex vivo splenocytes from groups of
mice, each group immunized with one of the five constructs
encoding a RAH minigene inserted at different locations (Fig.
2a), secreted IFN-γwhen cultured in vitrowith, but not without,
RAH peptide (Fig. 2b). Ex vivo splenocytes from mice
immunized with HBsAg wild type (W/T) DNA cultured with
RAH peptide did not secrete IFN-γ above the level observed
when cultured without peptide ( data not shown).five endogenous CTL epitopes, (black boxes) located in the transmembrane and
Table 1
HBsAg CTL epitopes
Designation Sequence MHC
restriction
Reference
VLQ 13VLQAGFFLL21 HLA A⁎0201 Chisari and Ferrari
(1995)
IPQ 28IPQSLDSWWTSL39 H-2Ld Ando et al. (1993)
FLG 41FLGGTPVCL49 HLA A⁎0201 Chisari and Ferrari
(1995)
GLS 184GLSPTVWLSV193 HLA A⁎0201 Nayersina et al. (1993)
SIL 206SILSPFLPLL215 HLA A⁎0201 Chisari and Ferrari
(1995)
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zation with each of these five constructs expressing a RAH
minigene inserted at different locations would induce CTL
following restimulation, which would kill target cells expressingFig. 2. (a) Schematic of chimeric HBsAg DNA constructs in each of which an endog
HPV E7 CTL epitope RAH. (b, c) Immunization with chimeric HBsAg DNAs enc
mice (3 per group) were immunized twice i.d. with DNA or once s.c. with RAH pepti
assay using splenocytes harvested at 14 days (DNA immunizations) or 10 days (pep
peptide (left histogram bar) or without peptide (right histogram bar), as shown. Bar
memory responses. Groups of mice were immunized as above. Percent cytotoxicity o
a 51Cr release assay using EL4.A2 target cells pulsed with RAH peptide or without p
(standard deviations were always less than 3%).the RAHCTL epitope. Splenocytes fromDNA-immunizedmice
were restimulated in vitro for 6 days with RAH peptide, and
reacted with peptide-pulsed H-2b target cells. Restimulated
splenocytes from all the immunized groups of mice killed RAH
peptide-pulsed targets (Fig. 2c). Notably the efficiency of killing
was comparable with that seen in identically restimulated
splenocytes from mice immunized with high dose RAH peptide
plus adjuvant (Fig. 2c). Immunization with high-dose CTL
epitope peptide plus adjuvant is a powerful inducer of CTL
responses and a ‘standard’ against which other CTL-inducing
modalities may be compared (Doan et al., 1998).
Taken together, these data indicate that replacement of
DNA encoding HBsAg-specific CTL epitopes with DNA
encoding a foreign CTL epitope at specific locations within the
HBsAg molecule to generate recombinant DNA immunogens,
engenders effector and memory CTL responses to the foreign
epitope.enous CTL epitope (Fig. 1) was deleted and replaced with a single copy of the
oding a single copy of RAH elicits RAH-directed CTL responses. Groups of
de plus adjuvant. (b) Effector IFN-γ-secreting cells were quantified by ELISPOT
tide immunization) after immunization, and incubated for 15–18 h. with RAH
s represent means±standard deviation of 3 replicates. (c) Epitope-specific CTL
f splenocytes restimulated for 6 days in vitro with RAH peptide was measured in
eptide as shown. Data points represent means of 3 replicates±standard deviation
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an inserted foreign epitope elicits improved insert-directed
CTL responses
We asked whether rHBsAg DNAvaccines encoding multiple
copies of a foreign CTL epitope would elicit superior CTL
responses compared to a rHBsAg DNA vaccine encoding a
single copy of the foreign epitope. Recombinant HBsAg DNAs
were constructed to encode three, four and five copies of RAH
CTL epitope (RAHx3, RAHx4, and RAHx5; Fig. 3a), at
locations individually validated to express inserted RAH for
immune response induction (Fig. 2a). IFN-γ ELISPOT assays
were conducted on splenocytes harvested ex vivo, and also after
a further 6-day restimulation in vitro with RAH peptide, from
groups of mice immunized with the four constructs expressing
one, three, four or five RAH minigenes. Both ex vivo (Fig. 3b)
and post-restimulation (Fig. 3c) splenocytes from mice immu-
nized with rHBsAg DNA encoding one or more copies of the
RAH minigene secreted substantial amounts of IFN-γ when
cultured with, but not without, RAH peptide. The numbers of
secreting splenocytes from mice immunized with RAHx3,
RAHx4 and RAHx5 were significantly higher than splenocytesFig. 3. (a) Schematic of rHBsAg DNA constructs in which 1, 3, 4 or 5 endogenous C
CTL epitope RAH. (b–d) Immunization with chimeric HBsAg DNAs encoding RAH
i.d. with DNA or once s.c. with RAH peptide plus adjuvant (b, c). IFN-γ-secretin
immunizations) after immunization, were quantified by ELISPOT assay either ex viv
were incubated for 15–18 h. with RAH peptide or without peptide, as shown. Bars
immunized as above. Percent cytotoxicity of splenocytes restimulated with RAH pep
RAH peptide or without peptide as shown. Data points represent means of 3 replicafrommice immunized with RAHx1.ΔGLS (ex vivo splenocytes,
pb000.1; post-restimulation splenocytes pb0.001). The num-
bers of IFN-γ secreting splenocytes from mice immunized with
RAHx3, RAHx4 and RAHx5 did not differ significantly from
each other (ex vivo, pN0.5; post-restimulation pN0.7). Ex vivo
splenocytes from mice immunized with pHBsAg not encoding
RAH (RAHx0) did not secrete IFN-γ above background when
cultured with RAH peptide (Figs. 3b, c).
Together these data indicate that immunization with
rHBsAg DNA vaccines encoding multiple (three, four or
five) copies of a foreign CTL epitope elicits superior effector
(ex vivo) and memory (post-restimulation) CTL responses,
compared with a rHBsAg DNA vaccine encoding a single copy
of the foreign CTL epitope. The data also indicate that provision
of four or more copies of the foreign minigene in rHBsAg DNA
does not augment the responses seen by provision of three
copies.
We also measured RAH-directed memory CTL responses by
51Cr release cytotoxicity assay. Restimulated splenocytes from
mice immunized with rHBsAg vaccines encoding single or
multiple copies of RAH epitope specifically killed RAH
expressing target cells (Fig. 3d).TL epitopes (see Table 1 and Fig. 1) were deleted and replaced with the HPV E7
elicits RAH-directed CTL responses. Mice (3 per group) were immunized twice
g splenocytes harvested at 14 days (DNA immunizations) or 10 days (peptide
o (b) or after 6 days of restimulation in vitro with RAH peptide (c). Splenocytes
represent means±standard deviation of 3 replicates. (d) Groups of mice were
tide was measured in a 51Cr release assay using EL4.A2 target cells pulsed with
tes±standard deviation. (Standard deviations were always less than 3%.)
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versus a single copy of a tumor epitope does not significantly
improve tumor prevention
The HPV 16 E7 oncoprotein is necessary for the maintenance
of the transformed phenotype in HPV-associated squamous
cancers (von Knebel et al., 1994), and so E7 functions as a tumor
specific antigen to which immunomanipulative therapies may be
directed (Tindle, 2002; Frazer, 2004). RAH-directed CTL
protect against the growth of HPV16 E7 expressing tumors in
H-2b mice (Feltkamp et al., 1993) thus providing a model of
HPV-associated tumor protection in humans. We asked whether
immunization with rHBsAg DNA vaccines encoding three
copies of the RAH epitope would provide superior protection
against subsequent challenge with E7-expressing TC-1 tumor
(Lin et al., 1996) compared to immunization with rHBsAg DNA
vaccines encoding a single copy. As a single copy vaccine, we
used the rHBsAg construct in which the RAH tumor epitope was
inserted at the C′ terminalΔGLS site (RAHx1.ΔGLS, Fig. 2(a)).
Two of seven mice per group immunized with RAHx0,
RAHx1.ΔGLS, or RAHx3, were sampled to confirm induction
of RAH-directed effector CTL by IFN-γ ELISPOT assay (Fig.
4a). In agreement with the above findings, mice immunized with
rHBsAg DNA encoding three copies of RAH elicited a sig-Fig. 4. Recombinant HBsAg DNA encoding one or three copies of the RAH CTL epit
(7 per group) were immunized twice i.d. with RAHx0, RAHx1.ΔGLS, RAHx3. IFN
group were quantified by ELISPOT assay with or without RAH peptide as shown. B
tumor in immunized mice and controls. The remaining seven mice per group were c
immunization, and tumor growth monitored as percentage of mice with palpable tum
animal ethics requirements. Results are expressed as surviving mice (%) at the indicnificantly greater effector response than mice immunized with
rHBsAg encoding a single copy of RAH (Fig. 4a; pb0.001).
The remaining five mice per group were challenged with TC-1
tumor cells, and tumor growth monitored over a 24-day period.
Mice were euthanized when tumors reached 500 m3 in area (in
accord with ethical guidelines). 80% and 100% of mice
immunized with RAHx1.ΔGLS and RAHx3 respectively
survived to 24 days (difference not significant; pN0.05). In
contrast, significantly fewer (20%) of the mice immunized with
RAHx0 survived to day 24 (pb0.04) (Fig. 4b). These data
indicate that immunization with rHBsAg DNA vaccines
encoding the RAH epitope elicits CTL responses associated
with protection against establishment of E7-expressing tumor,
and that rHBsAg DNA encoding one copy of RAH is not
significantly less effective in invoking protection than rHBsAg
DNA encoding three copies, at the doses used.
Immunization with rHBsAg DNA encoding multiple copies
versus a single copy of a tumor epitope does not significantly
improve tumor therapy
We evaluated the efficacy of rHBsAg DNA encoding one
copy (RAHx1.ΔIPQ and RAHx1.ΔSIL, Fig. 3a) and three
copies (RAHx3) of the RAH epitope as therapeutic vaccines forope of HPV16 E7 protects against challenge with E7-expressing tumor. (a) Mice
-γ-secreting splenocytes harvested at 14 days from two representative mice per
ars are means±standard deviation of 3 replicates. (b) Growth of E7-expressing
hallenged with 2×105 E7-expressing TC-1 tumor cells 14 days after the second
or. Mice with tumors exceeding 500 mm3 were euthanized in accordance with
ated time points.
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TC-1 tumor cells. Commencing 3 days later, mice were im-
munized three times with rHBsAg DNAvaccines encoding one
or three copies of the RAH epitope (Fig. 5). 14 days after the
final immunization, three representative mice of thirteen per
group immunized with RAHx1.ΔIPQ, RAHx1.ΔSIL, or
RAHx3 were sampled to confirm induction of RAH-directed
effector CTL by IFN-γ ELISPOT assay. As expected, mice
immunized with rHBsAg DNA encoding three copies of RAH
displayed a significantly greater effector response than mice
immunized with rHBsAg encoding a single copy of RAH
(pb0.001) (Fig. 5a). In addition, we confirmed that restimulated
splenocytes from the representative mice immunized with
rHBsAg DNA encoding the RAH epitope specifically killed
target cells pulsed with RAH peptide, and target cells expressing
whole E7 protein (Fig. 5b).
Palpable tumor incidence was followed to 80 days. By day
11, tumors were palpable in 60% of mice immunized with wild-
type HBsAg DNA (RAHx0). In contrast, palpable tumor onset
was delayed in mice immunized with rHBsAg DNA vaccines
encoding the RAH epitope. Significantly fewer (30% or less;
pb0.05) of the mice immunized with rHBsAg DNA vaccines
encoding one or three copies of the RAH epitope developed
palpable tumor. There was no significant difference in tumor
incidence among groups of mice immunized with the vaccines
encoding one copy of RAH, or three copies of RAH (pN0.8)
(Fig. 5c).
Tumor volumes were recorded. Beyond 20 days tumors were
significantly smaller in all groups of mice immunized with
rHBsAg DNA vaccines encoding the RAH epitope compared
with mice immunized with wild-type HBsAg DNA (pb0.001)
(Fig. 5d). There was no significant difference in tumor volumes
between mice immunized with rHBsAg encoding a single copy
of RAH epitope (RAHx1.ΔIPQ and RAHx1.ΔSIL) and mice
immunized with rHBsAg encoding three copies of RAH epitope
(pN0.7).
We also examined whether immunization would retard the
growth of well-established palpable tumors. Groups of nine
mice with TC-1 tumors measuring at least 80 mm3 were
immunized with rHBsAg DNA vaccines encoding one copy
(RAHx1.ΔSIL) or three copies of the RAH epitope. Both these
RAH-encoding vaccines slowed the growth of tumor compared
to wild type (W/T) HBsAg vaccine when measured at 19 days,
although the difference was barely significant (P=0.049). There
was no significant difference in degree to which tumor growth
was slowed by rHBsAg vaccine encoding one copy of RAH or
the rHBsAg vaccine encoding three copies of RAH (pN0.3)
(Fig. 6).
Mice cured of tumor by therapeutic immunization with tumor
epitope-encoding rHBsAg vaccines retain long-term anti-tumor
immunity
We examined whether mice which were cured of their tumors
by immunization with rHBsAg DNA encoding one or multiple
copies of RAH tumor epitope retained long term RAH-directed
CTL responses and resistance to the growth of a subsequentchallenge with TC-1 tumor. Representativemice which had been
inoculated with TC-1 tumor cells and subsequently therapeuti-
cally immunized with chimeric HBsAg DNAvaccines encoding
one or three copies of RAH epitope to resolve tumor (see Fig. 5,
above), were evaluated at 100 days for RAH-directed memory
CTL responses. IFN-γ ELISPOT assays were conducted on
splenocytes after restimulation in vitro. Post-restimulation
splenocytes frommice immunized with rHBsAg DNA encoding
one or three copies of RAH secreted substantial amounts of IFN-
γ when cultured with, but not without, RAH peptide (Fig. 7a).
The numbers of IFNγ-secreting splenocytes from mice
immunized with RAHx3, was significantly higher than the
number IFNγ-secreting splenocytes from mice immunized with
rHBsAg encoding a single copy of RAH (RAHx1.ΔIPQ or
RAHx1.ΔSIL) (pb0.001) in accord with findings reported in
Fig. 3c.We also measured RAH-directed CTL responses by 51Cr
cytotoxicity assays. Restimulated splenocytes from mice
immunized with HBsAg encoding a single copy of RAH or
with RAHx3 showed high levels of cytotoxicity towards RAH-
expressing target cells (Fig. 7b).
The remaining members of the groups of mice previously
cured of tumor by rHBsAg DNA immunization N100 days
earlier were rechallenged with 2×105 TC-1 tumor cells. One
hundred percent of mice which had previously received
RAHx1.ΔIPQ, RAHx1.ΔSIL or RAHx3 vaccines N100 days
earlier were protected against the growth of tumor, whereas all
of a group of unimmunized mice developed tumors.
Together these results demonstrate that mice cured of
previous tumor by therapeutic immunization with rHBsAg
DNA vaccines encoding either a single copy or three copies of
RAH epitope retain RAH-directed memory CTL responses, and
are protected against subsequent tumor challenge, for at least
100 days.
Discussion
The adaptive cellular arm of the immune response plays a
major role in the control of tumors and pathogens and the
response is mediated largely by CD8+ CTLs. There are
difficulties in deriving vaccines capable of delivering multiple
CTL epitopes which are acceptable for humans (Gupta and
Siber, 1995). CTL epitopes delivered as peptide mixes have
generally proved ineffective, may require a source of CD4
‘help’, and are hampered at the regulatory level by restriction on
the use of adjuvants capable of inducing effective cellular
responses. Vaccines containing recombinant tumor- and patho-
gen-derived proteins are difficult to construct, and are further
limited by availability of acceptable vector systems for use in
humans.
HBsAg, already licensed as the human vaccine for hepatitis B
virus (HBV) infection, is an attractive vector for the delivery of
epitopes from tumors and other pathogens, from both a
regulatory and scientific point of view (Davis et al., 1993;
Schirmbeck et al., 1994). While HBsAg has been used
experimentally as a carrier for foreign B cell epitopes for
antibody induction, there have been few reports exploiting the
inherent immunogenicity of HBsAg to deliver foreign CTL
Fig. 5. Recombinant HBsAg DNA vaccines encoding one or three copies of the RAH CTL epitope of HPV16 E7 protect against the growth of pre-existing
E7-expressing tumor. Five groups of mice (13 per group) were injected s.c. with 5×104 TC-1 tumor cells and the tumor allowed to growth for 3 days. The groups were
then immunized 3 times at 4-day intervals with either RAHx0, RAHx1ΔIPQ or RAHx1ΔSIL; (Fig. 2a) or with RAHx3, and subsequent tumor growth quantified. To
confirm that immunized mice were mounting E7-directed CTL responses, IFN-γ-secreting splenocytes harvested from three representative mice per group 6 day after
the final immunization were quantified by ELISPOT assay with or without RAH peptide (a), or restimulated in vitro and reacted with RAH-expressing target cells in
51Cr release assay (b). Bars are means±standard deviation of 3 replicates. Tumor growth was followed in the remaining mice and expressed as % mice with palpable
tumor at the indicated time points (c), and as tumor volumes (mean±S.E.M.) of those mice with persisting tumor (d).
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Fig. 6. Recombinant HBsAg DNAvaccines encoding one or three copies of the
RAH CTL epitope of HPV16 E7 protect against the growth of well-established
E7-expressing tumor. Groups of mice with TC-1 tumors measuring 80 mm3
were immunized with rHBsAg DNA encoding 1 copy (RAHx1.ΔSIL) or three
copies (RAHx3) of RAH epitope. Tumor volumes of individual mice were
recorded at intervals to 19 days.
Fig. 7. Longevity of anti-tumor response. Groups of mice were cured of TC-1
tumor by three rHBsAg immunizations with rHBsAg containing 1 copy of RAH
(RAHx1.ΔIPQ or RAHx1.ΔSIL) or 3 copies of RAH (RAHx3). RAH-directed
memory CTL responses were evaluated in two representative mice per group.
Splenocytes harvested from two representative mice per group were
restimulated for 6 days in vitro with RAH peptide and quantified by ELISPOT
assay with or without specific peptide (RAH) (a), or by 51Cr release assay (b).
Bars are means±standard deviation of 3 replicates.
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Michel et al., 2007). We have demonstrated that tumor- and
pathogen-associated CTL epitopes may be genetically incorpo-
rated into HBsAg by replacement of two endogenous CTL
epitopes (IPQ and GLS) which when delivered as plasmid DNA
vaccines elicit CTL-associated disease protective responses
(Woo et al., 2006).
The vaccine for HBV is administered as antibody-inducing
HBsAg virus-like particles. However, data suggests that DNA
may be the preferred modality for CTL induction (Davis et al.,
1996, 1997). That a single low-dose injection of HBsAg
plasmid DNA gives CTL detectable for many months post
vaccination (Davis et al., 1993; Edgtton, unpublished data)
suggests that continuous exposure of small doses of antigen
provided from on-going DNA transcription may be necessary to
maintain immunity. Such priming with prolonged exposure to
antigen predisposes the response in the direction of ‘central
memory’ T cells (TCM) (Wherry et al., 2005) and enables
conversion of effector memory T cells (TEM) to TCM (Wherry et
al., 2003), which afford greater protection against tumors
(Klebanoff et al., 2005) and viral infection (Wherry et al., 2003;
Zanetti and Franchini, 2006). A variety of cells are likely to betransfected by injected HBsAg DNA, though only transfection
of “professional” antigen presenting cells (APCs) leads to
activation of the CTL response via the intracellular (endogen-
ous) processing pathway (Sbai et al., 2002). VLP formation
within the APC is not an essential requirement for this to occur
(Sbai et al., 2002). Secretion of HBsAg VLPs (e.g. by DNA-
transfected muscle cells) allows uptake of secreted particles by
APCs for processing via the ‘exogenous pathway’ (Davis et al.,
1993), thus providing a second mechanism for HBsAg CTL
generation (Schirmbeck and Reimann, 2002). Thus the strong
CTL responses induced by HBsAg DNA vaccination, requiring
ca. 2500-fold lower dose than conventional DNAvaccines (Roy
et al., 2000), may be explained in terms of prolonged and higher
expression, secretion for uptake of VLPs by APC, superior
antigen processing and the presence of multiple T-helper
epitopes in the HBsAg backbone.
In the current study, we used the epitope replacement strategy
developed in our laboratory (Woo et al., 2006) to extend to five
sites (ΔVLQ, ΔIPQ, ΔFLG, ΔGLS and ΔSIL: Fig. 1) where
DNA encoding endogenous HBsAg CTL epitopes could be
deleted and replaced with DNA encoding a foreign CTL epitope
(from the E7 oncoprotein of HPV16) to derive five rHBsAg
DNA vaccines (Fig. 2a). Each of these vaccines elicited E7-
directed effector and memory CTL responses, though with
371O. Haigh et al. / Virology 368 (2007) 363–375varying efficiency (Figs. 2b, c). Our data do not address the
cause of this variation though it likely relates to translational
efficiency, and/or efficacy of antigen processing and presenta-
tion, of the various HBsAg recombinants.
Since the magnitude of a primary T cell response parallels
antigen dose (Wherry et al., 1999; Kaech and Ahmed, 2001)
and the pool of memory T cells surviving apoptosis reflects
the magnitude of the primary expansion (Wherry et al., 1999),
we were interested to determine whether provision of multiple
copies of the inserted minigene encoding the RAH tumor
epitope in rHBsAg DNA vaccines would augment the tumor
epitope-directed CTL response. Thus, we constructed a panel
of rHBsAg DNA vaccines encoding multiple copies of the
tumor epitope, each copy at one of the above predetermined
sites (Figs. 2 and 3a), and investigated the immunogenicity of
these vaccines. Since our earlier data demonstrated that two
copies of a minigene encoding a foreign epitope (from RSV)
did not significantly improve immunogenicity over a single
copy (Woo et al., 2006), we elected in the present study to
examine vaccines encoding three copies or more of a foreign
epitope (from HPV). To address whether insert at each of the
sites was immunogenic in the context of multicopy rHBsAg
vaccines we inserted DNA encoding five different foreign
CTL epitopes into a single rHBsAg vaccine, one epitope at
each of the five sites to show that this rHBsAg DNA vaccine
elicited CTL to each of the encoded foreign CTL epitopes
simultaneously (data not shown).
We demonstrate that immunization with rHBsAg DNA
vaccines encoding multiple (three, four or five) copies of the
RAH tumor epitope elicits superior effector and memory CTL
responses compared with a rHBsAg DNA vaccine encoding a
single copy of the foreign CTL epitope. This conclusion held
when the tumor epitope was encoded at any of three sites
(ΔGLS, ΔIPQ, or ΔSIL) in a single copy construct (Figs. 3, 5,
and 7). The data also indicate that four or five copies of the tumor
epitope DNA encoded in rHBsAg did not further improve the
CTL responses elicited by rHBsAg encoding three copies (Fig.
3).
We examined the capacity of rHBsAg DNA vaccines
encoding a single copy or three copies of the tumor epitope
to afford tumor protection. We found that the weaker effector
CTL response induced by rHBsAg encoding a single copy (Fig.
4a) was nonetheless associated with a potent protective
response to challenge with E7-expressing tumor (Fig. 4),
similar to the protective response induced by immunization
with rHBsAg encoding three copies, where the effector CTL
response was significantly stronger. These novel data also
demonstrate that rHBsAg DNA vaccine encoding a single copy
of the RAH tumor antigen inserted at the C′ terminus
(RAHx1.ΔGLS) is as effective at mediating tumor prevention
as a rHBsAg DNA vaccine encoding a single copy of the RAH
tumor antigen inserted at the N′ terminus (RAHx1.ΔIPQ)
(Woo et al., 2006). Furthermore we extend these and our
previous findings on tumor prevention (Woo et al., 2006) to
demonstrate that the weaker effector CTL response induced by
immunization of tumor-bearing mice with rHBsAg encoding a
single copy of the tumor epitope did not lessen the therapeuticeffect afforded by immunization with rHBsAg encoding three
copies of the tumor epitope (Figs. 5a, c). Immunization with
rHBsAg encoding a single copy or three copies of the tumor
antigen were both associated with powerful memory cytotoxic
responses in these mice which specifically killed both epitope-
pulsed target cells and target cells constitutively expressing
whole tumor antigen (E7) (Fig. 5b). Furthermore, mice cured of
their tumors 100 days previously by immunization with
rHBsAg DNA containing one or three copies of tumor epitope
were both totally protected against further tumor challenge.
These data suggest that enhancement of the effector response
following immunization with rHBsAg DNA encoding multiple
versus single copies of tumor antigen is not necessary for
optimal and long-lived tumor protection. This is consistent with
the view that tumor protection is brought about by central
memory T cells (TCM) stimulated by tumor challenge (Zanetti
and Franchini, 2006).
Overall, the data confirm the efficacy of HBsAg DNA as a
vector for the delivery of foreign CTL epitopes. They suggest
that the magnitude of the CTL responses may be enhanced by
provision of multiple copies of minigenes encoding a foreign
CTL epitope, though in our system at least, the enhancement
effect plateaus beyond provision of three copies. The data also
indicate that increasing the size of the effector response by
provision of multiple copies of a tumor epitope is not effective in
increasing the levels of tumor protection, at least under the
conditions of our experiments. While much of the antibody
response to HBsAg is directed to determinant(s) in the external
‘a’ loop (see Fig. 1), and the CTL epitope replacements we report
are located in transmembrane and external regions elsewhere,
there is possibility that our recombinant vaccines would also
elicit HBsAg antibody were appropriate conditions chosen for
immunization (i.e. DNA injection into traumatized muscle and
serology 6–12 weeks later) (Schirmbeck and Reimann, 2001).
While our data clearly indicate that rHBsAg DNA encoding
three to five copies of the RAH minigene is more immunogenic
than DNA encoding a single copy, factors in addition to, or
other than, simple increase of copy number may contribute to
this enhancement. Injected DNA encoding HBsAg DNA is
likely to transfect a variety of cells, though only transfection of
“professional” antigen-presenting cells (APCs) leads to activa-
tion of the CTL response via the intracellular (endogenous)
processing pathway (Sbai et al., 2002). Following a single i.m.
injection of HBsAg DNA, the antigen can be found in
circulation for at least 1 month, suggesting sustained expression
(Leclerc et al., 1997). Particle formation within the APC is not
an essential requirement for this to occur (Sbai et al., 2002).
Secretion of HBsAg particles (e.g. by DNA-transfected muscle
cells) allows uptake of secreted particles by APCs for
processing via the ‘exogenous’ pathway (Davis et al., 1993),
thus providing a second mechanism for HBsAg CTL generation
(Schirmbeck and Reimann, 2002). We have previously reported
variable particle formation among rHBsAg DNAs encoding
inserted foreign CTL epitopes (Woo et al., 2006). In short,
particle formation, plus a range of other variables (i.e. variable
antigen expression, stability of the HBsAg DNA and the
expressed rHBsAg protein vivo, antigen processing, and
372 O. Haigh et al. / Virology 368 (2007) 363–375availability of T cell epitopes from the genetically engineered
HBsAg gene) are all factors which might contribute to the
differences in immunogenicity we report among the constructs
used in the present study.
As well as having generic implication for the construction of
chimeric HBsAg vaccines, our results also have specific
implications for the development of a therapeutic vaccine for
HPV-associated squamous carcinomas. Cervical carcinoma is
recognized by the World Health Organization as being 100%
attributable to HPV (Bosch et al., 2002), of which the ‘high-risk’
genotype HPV16 accounts for ca 60%. Cervical cancer is the
leading cause of cancer-related death in women in developing
countries, and causes ca 400,000 deaths per annum worldwide.
While recently introduced prophylactic vaccines to prevent HPV
infection are likely to decrease cervical cancer incidence, ca.
5 million women are predicted to die during the 10–20-year
period until the effect of the vaccine is felt (Frazer, 2004).
Uncontrolled expression of the HPV 16 E7 protein transforms
cervical keratinocytes in a multi-step process which requires the
persistence of the E7 oncoprotein in order for the cells to remains
transformed. The E7 protein thus functions as a tumor-specific
antigen to which immunotherapeutic strategies have been
directed both in animal models of HPV associated tumor
development, and in human clinical trials of therapeutic vaccines
for cervical cancer (Fiander et al., 2006; Borysiewicz et al.,
1996; Frazer et al., 2004). E7-directed protection against the
HPV16 E7-expressing murine tumor TC-1 is provided by a
CD8+ CTL response to the RAH epitope used in the present
study. This animal tumor model provides a surrogate for
vaccine-induced CTL protection against E7-expressing cervical
carcinoma in women, and for other HPV16 associated squamous
cell cancers. A putative therapeutic vaccine for cervical cancer
requires a powerful antigen delivery system to compensate for
the suboptimal antigen presentation at the tumor site, and the
local immunosuppressive milieu of the cervix (Tindle, 2002).
Approaches taken so far of immunizing with peptides, whole
proteins in recombinant viral vector, or as naked DNA to treat
cervical cancer have produced disappointing results in clinical
trials (Tindle, 2002). Such approaches have been limited by the
availability of suitable adjuvants predisposing to a Th1 response
and licensed for use in humans, by pre-existing immunity to
vector abrogating E7-directed responses, or by regulatory issues
surrounding live vectors. Our present study suggests the
application of HBsAg, already licensed as a human vaccine,
for the delivery of E7-directed CTL responses for therapy of
HPV16 associated cancers.
In summary, we demonstrate the efficacy of the replacement
of DNA encoding endogenous CTL epitopes with DNA
encoding a foreign tumor epitope at multiple sites within the
HBsAg gene to generate tumor protective rHBsAg DNA
vaccines. We show that while encoding three or more copies
of the tumor epitope enhances CTL induction, it does not serve
to augment tumor protection. There are clear implications for
strategies for constructing recombinant HBsAg vaccines. We
consider the use of rHBsAg vaccines in the context of a putative
therapeutic vaccine for HPV-associated cervical and other
cancers.Materials and methods
Cloning procedures
The plasmid pcD3-HBsAgS (ayw subtype) (Netter et al.,
2001) was engineered to delete the HBsAg-specific CTL
epitopes VLQ, IPQ, FLG, GLS and SIL (Table 1), and to
introduce the restriction enzyme sites BsiW1, NheI, BspE1,
BlpI and SacII respectively by PCR-driven site-directed
mutagenesis. Synthetic oligonucleotides encoding the RAH
epitope were inserted into HBsAg through systematic sub-
cloning into these restriction sites to create a series of constructs
(Figs. 2a and 3a). Due to reading frame shifts caused by addition
of restriction sites, codons for alanine and leucine (AA or A and
AL) were included in the insert sequences at the 5′ and 3′ ends
of the RAH oligomers. Standard molecular cloning and plasmid
purification procedures were used. Positive clones were
expanded using Wizard Plus SV minipreps DNA purification
system (Progen, Australia) or EndoFree Plasmid Giga Kit
(Qiagen, Australia) for DNA immunization. Sequences of
constructs were verified via Terminator Sequencing (ABI) Big
Dye 3.1.
Mice
A2.1Kb mice make CTL responses restricted through H-2b
class 1 molecules. Mice were housed under specific pathogen-
free conditions, and used at 7–15 weeks of age. Experiments
were conducted in accord with institutional animal ethics
guidelines.
Peptides
Peptides were synthesised using F-moc chemistry and
analysed by HPLC and by amino acid analysis by Chiron
Mimotopes (Melbourne, Australia).
Immunization and restimulation of splenocytes
Mice were immunized twice at a 2-weekly intervals
intradermally (i.d.) in the ear with 100 μg of purified plasmid
DNA. 2 weeks later, spleens were removed and either the
effector T response was quantified in ELISPOT assay ex vivo, or
the splenocytes were restimulated in vitro for 6 days as
described (Doan et al., 1998) with 1 μg/ml cognate peptide, and
memory T cell response quantified by ELISPOT assay and/or
51Chromium release assay. For peptide immunizations, mice
were immunized subcutaneously (s.c.) at the tail base with
50 μg peptide+0.25 μg tetanus toxoid (TT) as a source of
T-helper epitopes+10 μg Quil A adjuvant. 10 days later, spleens
were harvested and splenocytes were restimulated as above.
Cells
EL4.A2 cells (Doan et al., 2005) and EL4.E7 cells are
susceptible to specific CTL lysis through the H-2b restriction
pathway. EL4.E7 cells were derived by transfection of EL4 cells
373O. Haigh et al. / Virology 368 (2007) 363–375with the pJ4ΩE7 expression plasmid as described (Tindle et al.,
1995). TC-1 is a tumor cell line derived from primary lung
epithelial cells of C57BL/6 (H-2b) mice by co-transfection with
HPV16 E6, E7 and ca-Ha ras oncogenes (Lin et al., 1996).
Cells were maintained as described (Doan et al., 1998). TC-1
cells were prepared for injection in Hank’s balanced salt
solution.
Murine IFN-γ ELISPOT assay
Epitope-specific gamma interferon (IFN-g)-secreting spleen
cells were enumerated ex vivo by an enzyme-linked immuno-
spot (ELISPOT) assay with minimal CD8+ T-cell epitope
peptides, essentially as described (Wiethe et al., 2003). IFN-g
spots were counted using an AID EliSpot reader system. Results
were calculated as IFN-γ-positive cells/106 spleen cells.
Experimental values were compared for significant difference
using chi-square analysis.
51Chromium release cytotoxicity assay
Assays were conducted as previously described (Doan et al.,
1998). In summary, target cells (104 per well) sensitised at 37 °C
for 1 h with 1 μg/ml cognate or irrelevant peptide, or medium
alone, and labelled with 100 μCi 51Chromium (Cr), were
incubated with effector cells at various effector: target cell ratios
in triplicate in 96-well microtitre plates. Negative controls
included wells containing target cells but no effector cells
(= ‘background’). Supernatants were harvested from CTL
assays at 4 h, and 51Cr release quantified by gamma counting.
Results are expressed as percent cytotoxicity±standard devia-
tion (51Cr release in experimental wells−background/deter-
gent-mediated total release−background)×100%.
Tumor prevention
Groups of mice were immunized with 100 μg plasmid DNA
id, or 100 μg of E7 peptide+ tetanus toxoid+Quil A sc. TC-1
cells, which express the E7 tumor-associated antigen of human
papillomavirus type 16, were subsequently injected (2×105 in
0.1 ml Hank’s buffered salt solution) s.c. on the flank. (The
tumor dose was predetermined by titration experiments to
discern a minimal dose, giving rise to tumor in 80–100% of
unimmunized mice.) Tumor growth was monitored at intervals,
and mice were euthanized when tumor volume exceeded
500 mm3. Unimmunized or HBsAg wild type (W/T) immu-
nized mice received the same number of TC-1 cells and served
as a control. Results are presented as Kaplan–Meier curves of %
surviving mice, and treatment groups were compared using the
Log Rank statistic.
Tumor therapy
Non-palpable tumor
Groups of mice were injected with 5×104 TC-1 cells
subcutaneously on the flank. At 3 days later, the mice were
immunized three times at 4-day intervals, and subsequent tumorgrowth quantified as number of tumor-bearing mice and as
tumor volume. Tumor volume was derived from caliper
measurement in two perpendicular dimensions by the formula
S2L, where S is the shorter dimension and L is the longer
dimension of the tumor. Tumor volumes between groups were
compared by analysis of variance (ANOVA).
Palpable tumor
Groups of mice were injected with TC-1 cells as above.
When developing tumors became palpable ca. 14 days later
with approximate volumes of 80 mm3, mice were immunized 3
times at 3-day intervals, and thereafter tumor volume was
monitored every 3–4 days. Tumor volumes were measured as
above. Results are presented as Kaplan–Meier curves of %
tumor-free mice, and treatment groups were compared using the
Log Rank statistic.
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